UK property developer The Ability Group acquired Hampton by Hilton hotel at Bristol Airport from a Chinese investment vehicle while Regenacy Pharmaceuticals has raised $30 million in a Series A round of financing jointly led by Cobro Ventures and Taiwania Capital.
UK-based Ability buys Bristol hotel from Chinese CIMC Capital
UK property developer The Ability Group has acquired Hampton by Hilton hotel at Bristol Airport for £24 million ($29 million), according to reports in local media.
Ability bought the hotel from CIMC Capital, an investment vehicle of Chinese state-owned logistics and energy equipment supplier China International Marine Containers (Group) Ltd (CIMC).
CIMC’s partnership with the 201-bedroom hotel started in 2015. The hotel was financed and owned by CIMC, while Hilton Worldwide managed it.
CBRE acted as an adviser for the deal.
Taiwania Capital co-leads $30m Series A round in Regenacy
US-based Regenacy Pharmaceuticals has raised $30 million in a Series A round of financing jointly led by US private investment firm Cobro Ventures and Taipei & Silicon Valley headquartered Taiwania Capital Management Corporation, according to a company statement.
Chinese healthcare focused venture capital firm 3E Bioventures Capital, Shanghai-based Yonghua Capital’s sister firm Yonjin Capital, drug discovery platform Viva Biotech Holdings and Ta ya Venture Holdings Limited have also participated in the current round. The other individual investors are undisclosed.
As part of the deal, Regenacy offered three seats on its board of directors to the investors.
The clinical-stage focused Regenacy was set up in 2016 following the acquisition of small molecule drugs company Acetylon Pharmaceuticals by the global drug developer Celgene. Regenacy is engaged in developing novel treatments for diabetes and peripheral neuropathies.
Proceeds will be used to facilitate a Phase 2 proof-of-concept trial for ricolinostat, an oral, selective histone deacetylase 6 (HDAC6) inhibitor, in diabetic peripheral neuropathy (DPN).
Established in 2017 by National Development Fund of the Executive Yuan of Taiwan and other investors, Taiwania Capital has focused on early-stage companies. It has launched two funds with a total size of $350 million.